51 | 5KZU |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
9-[[1-[8-methyl-8-(2-phenylethyl)-8-azoniabicyclo[3.2.1]octan-3-yl]triazol-4-yl]methyl]carbazole |
74S |
|
0.56 |
SHOW |
52 | 4DBM |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
(3-exo)-8,8-dimethyl-3-(4-{[(1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)-8-azoniabicyclo[3.2.1]octane |
0J0 |
|
0.55 |
SHOW |
53 | 2X00 |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
GYMNODIMINE A |
GYN |
|
0.55 |
SHOW |
54 | 6PV7 |
Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens |
P32297 (ACHA3_HUMAN) |
(S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE |
NCT |
|
0.55 |
SHOW |
55 | 5AFH |
Acetylcholine-binding protein | Lymnaea stagnalis |
P58154 (ACHP_LYMST) |
Alpha-Lobeline |
L0B |
|
0.54 |
SHOW |
56 | 5AFL |
Acetylcholine-binding protein | Lymnaea stagnalis |
P58154 (ACHP_LYMST) |
Alpha-Lobeline |
L0B |
|
0.54 |
SHOW |
57 | 5AFM |
Acetylcholine-binding protein | Lymnaea stagnalis |
P58154 (ACHP_LYMST) |
Alpha-Lobeline |
L0B |
|
0.53 |
SHOW |
58 | 5AFK |
Acetylcholine-binding protein | Lymnaea stagnalis |
P58154 (ACHP_LYMST) |
Alpha-Lobeline |
L0B |
|
0.53 |
SHOW |
59 | 2WNC |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
(3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-INDOLE-3-CARBOXYLATE |
TKT |
|
0.53 |
SHOW |
60 | 5LXB |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
palonosetron |
7A9 |
|
0.53 |
SHOW |
61 | 5AFN |
Acetylcholine-binding protein | Lymnaea stagnalis |
P58154 (ACHP_LYMST) |
Alpha-Lobeline |
L0B |
|
0.53 |
SHOW |
62 | 5OA0 |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
STRYCHNINE |
SY9 |
|
0.5 |
SHOW |
63 | 2W8G |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
(3-ENDO,8-ANTI)-8-BENZYL-3-(10,11-DIHYDRO-5H-DIBENZO[A,D][7]ANNULEN-5-YLOXY)-8-AZONIABICYCLO[3.2.1]OCTANE |
BS2 |
|
0.5 |
SHOW |
64 | 5O8T |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
STRYCHNINE |
SY9 |
|
0.49 |
SHOW |
65 | 5OAJ |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
(3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-INDOLE-3-CARBOXYLATE |
TKT |
|
0.49 |
SHOW |
66 | 2XNU |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
2-(2-(4-PHENYLPIPERIDIN-1-YL)ETHYL)-1H-INDOLE |
VU3 |
|
0.49 |
SHOW |
67 | 3SIO |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
METHYLLYCACONITINE |
MLK |
|
0.49 |
SHOW |
68 | 2YME |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
1-methyl-N-[(1R,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide |
CWB |
|
0.49 |
SHOW |
69 | 2Y57 |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
[(1R,5S)-8-PHENETHYL-8-AZABICYCLO[3.2.1]OCTAN-3-YL] BENZOATE |
V37 |
|
0.48 |
SHOW |
70 | 3SH1 |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
METHYLLYCACONITINE |
MLK |
|
0.48 |
SHOW |
71 | 2XYS |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
STRYCHNINE |
SY9 |
|
0.47 |
SHOW |
72 | 2Y56 |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
[(1S,5R)-8-[(2R)-2-HYDROXY-2-PHENYL-ETHYL]-8-AZABICYCLO[3.2.1]OCTAN-3-YL] BENZOATE |
V11 |
|
0.47 |
SHOW |
73 | 4WV9 |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
(3-exo)-8,8-dimethyl-3-[4-(pyridin-4-yl)-1H-1,2,3-triazol-1-yl]-8-azoniabicyclo[3.2.1]octane |
MD4 |
|
0.45 |
SHOW |
74 | 5OAL |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
STRYCHNINE |
SY9 |
|
0.45 |
SHOW |
75 | 5CFB |
Glycine receptor subunit alpha-3 | Homo sapiens |
O75311 (GLRA3_HUMAN) |
STRYCHNINE |
SY9 |
|
0.43 |
SHOW |
76 | 6UL5 |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 group M subtype B |
P03366 (POL_HV1B1) |
4-[(4-{4-[(E)-2-cyanoethenyl]-2,6-dimethylphenoxy}thieno[3,2-d]pyrimidin-2-yl)amino]-2-fluorobenzonitrile |
QAG |
|
0.43 |
SHOW |
77 | 6Y1Z |
5-hydroxytryptamine receptor 3A | Mus musculus |
P23979 (5HT3A_MOUSE) |
(3~{a}~{S})-2-[(3~{S})-1-azabicyclo[2.2.2]octan-3-yl]-3~{a},4,5,6-tetrahydro-3~{H}-benzo[de]isoquinolin-1-one |
O7B |
|
0.43 |
SHOW |
78 | 5OBG |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
STRYCHNINE |
SY9 |
|
0.41 |
SHOW |
79 | 6VM0 |
Glycine receptor subunit alphaZ1 | Danio rerio |
O93430 (GLRA1_DANRE) |
GLYCINE |
GLY |
|
0.41 |
SHOW |
80 | 6VM2 |
Glycine receptor subunit alphaZ1 | Danio rerio |
O93430 (GLRA1_DANRE) |
GLYCINE |
GLY |
|
0.41 |
SHOW |
81 | 3RQW |
Gamma-aminobutyric-acid receptor subunit beta-1 | Dickeya dadantii |
E0SJQ4 (E0SJQ4_DICD3) |
ACETYLCHOLINE |
ACH |
|
0.41 |
SHOW |
82 | 3JAD |
Glycine receptor subunit alphaZ1 | Danio rerio |
O93430 (GLRA1_DANRE) |
STRYCHNINE |
SY9 |
|
0.41 |
SHOW |
83 | 5TW3 |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 group M subtype B |
P03366 (POL_HV1B1) |
5-{2-[2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]-4-fluorophenoxy}-7-fluoronaphthalene-2-carbonitrile |
7N1 |
|
0.41 |
SHOW |
84 | 2XNV |
Soluble acetylcholine receptor | Aplysia californica |
Q8WSF8 (Q8WSF8_APLCA) |
2-(2-(4-PHENYLPIPERIDIN-1-YL)ETHYL)-1H-INDOLE |
VU3 |
|
0.41 |
SHOW |
85 | 6DTW |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 group M subtype B |
P03366 (POL_HV1B1) |
8-{2-[2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethoxy]-4-fluorophenoxy}-6-fluoroindolizine-2-carbonitrile |
H9Y |
|
0.41 |
SHOW |